Sign Up Today and Learn More About Synthekine Stock
Invest in or calculate the value of your shares in Synthekine or other pre-IPO companies through EquityZen's platform.
Synthekine Stock
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
About Synthekine Stock
Founded
2018
Headquarters
Menlo Park, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
Synthekine Press Mentions
Stay in the know about the latest news on Synthekine
Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024
businesswire • Nov 15, 2024
Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
businesswire • Nov 08, 2024
AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class
fiercebiotech • May 20, 2024
Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination ...
businesswire • May 20, 2024
Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment ...
finance • May 20, 2024
Synthekine Management
Leadership team at Synthekine
Chief Executive Officer
Debanjan Ray
Board Member
Julie Papanek Grant
Join now and verify your accreditation status to gain access to:
- Synthekine current valuation
- Synthekine stock price
- Available deals in Synthekine and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Synthekine stock?
Accredited investors can buy pre-IPO stock in companies like Synthekine through EquityZen funds. These investments are made available by existing Synthekine shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Synthekine stock?
Shareholders can sell their Synthekine stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."